Hints and tips:
Related Special Reports
...Timothy Mackey, professor of global health at University of California San Diego, predicted that other pharma companies would probably follow Eli Lilly and Pfizer....
...Ogilvy, which has previously worked with a host of pharma groups including Pfizer and Johnson & Johnson, is launching a business that offers vetted influencers to talk about illnesses and possible solutions...
...Soriot’s new pay deal comes after the company hit a $45bn sales target in 2023 that the chief executive had set in 2014 when the company fended off a takeover bid from US rival Pfizer....
...While some investors are sceptical of companies without long-term growth plans, she said Moderna had met every challenge....
...Its vaccine, a more traditional protein-based formulation combined with an adjuvant to boost its effectiveness, has been pitched to patients as a counterpoint to mRNA jabs from BioNTech/Pfizer and Moderna...
...Pfizer and BioNTech will dispute Moderna’s ability to withdraw the pledge when it did, given the World Health Organization did not declare the end of the “global health emergency” until March 2023....
...Pfizer’s efforts to develop an obesity pill have suffered setbacks. It has abandoned plans for two treatments already....
...Products and Alibaba Health Information Technology....
...But, 10 years this month after Pfizer arrived on the scene, the Frenchman has a fresh challenge: persuading investors that AstraZeneca’s best days are not behind it....
...The announcement comes after the pharmaceutical group requested in March that the European Union marketing authorisation for Vaxzevria be withdrawn, a request that was granted on Tuesday....
...The group had a market value of $600mn, as of market close on Friday....
...Pfizer is abandoning its plans for a weight loss pill to be taken twice a day after trials showed it caused significant side effects, in a setback to the US drugmaker’s effort to enter the fast-growing market...
...More than a billion dollars worth of Pfizer’s Covid-19 antiviral drugs procured in Europe have been wasted, according to health data, as tight controls over who can receive the medication left millions of...
...To make up for the shortfall in its pipeline, the US drugmaker earlier this year announced plans to buy Seagen, an oncology drugmaker, for $43bn; a deal Pfizer said it expected to close on Thursday....
...The World Health Organization has identified antimicrobial resistance as one of the top 10 global public health threats....
...Cuban is targeting the 38 per cent of private sector employers who self-insure at least one of their health plans....
...Pharmaceuticals groups Pfizer and Moderna, which have both faced criticism from fringe groups over their Covid-19 vaccines, also spent heavily on security for their CEOs last year....
...Panuwat’s company, Medivation, was bought in 2016 by Pfizer for $14bn. But the stock he purchased at the time was not that of Medivation....
...But having announced plans last year to have 75 health clinics by the end of 2024, Walmart is closing the venture after opening just 51....
...Germany’s BioNTech, which developed its own mRNA-based Covid vaccine with Pfizer, has also scaled back its African ambitions but has broken ground on a vaccine manufacturing site in Rwanda....
...Although the 21.1 per cent uptake of the GSK and Pfizer jabs is comfortably ahead of the 18 per cent forecast by health data provider Airfinity, GSK’s Arexvy jab has accounted for more than two-thirds of...
...Now, several members of the SBTi’s external advisory groups have sent a letter to the board, which has been seen by Moral Money, urging it to formally withdraw the statement....
...Last year Haleon, which manufactures consumer health goods including Sensodyne toothpaste and Panadol painkillers, sold athlete’s foot cream brand Lamisil to Sweden’s Karo Healthcare for £235mn....
...Pfizer and BioNTech each receive half of the gross profits of the vaccine. The US group plans to cut about $1bn in costs this year....
...J&J’s medtech division has outstripped the growth of the company’s drugs and diagnostics business, generating $30.4bn in sales last year, or 35 per cent of group revenues....
International Edition